Broad panels versus targeted testing compared for psychological burden when expanded coverage finds unrelated disease risks simultaneously
Broad genomic panels are tests that examine many genes or genetic regions at once, whereas targeted testing evaluates a defined gene, variant, or disease pathway. The available evidence suggests that broad panels can increase diagnostic yield and identify medically actionable risks, but they also create more opportunities for uncertain, unrelated, or simultaneous findings that may increase short-term worry, decision fatigue, and follow-up demands. Targeted testing generally limits psychological exposure and interpretation to the presenting clinical question, although it can miss additional risks. Evidence from the American College of Medical Genetics and Genomics (ACMG), the National Human Genome Research Institute, and systematic reviews indicates that most people do not experience lasting severe psychological harm after receiving genomic results, but distress is more likely when findings are unexpected, poorly explained, uncertain, or require several urgent decisions at once.
Psychological burden of broad-panel genomic testing
Psychological burden of broad-panel genomic testing is the emotional, cognitive, and behavioral impact associated with ordering, interpreting, receiving, and acting on results from a test that assesses multiple genes or conditions. The National Human Genome Research Institute describes genetic counseling as a process that helps people understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease. Applied to broad panels, this definition includes anxiety about disease risk, uncertainty about ambiguous findings, concerns about relatives, altered self-perception, and the practical burden of surveillance or preventive care.
The burden is not determined solely by the number of genes tested. It depends on the clinical context, the person’s baseline anxiety, the seriousness and actionability of the result, the quality of pretest counseling, and whether several findings are returned simultaneously. A targeted test may answer one focused question, while a broad panel can produce a mixture of positive, negative, carrier, pharmacogenomic, and uncertain results. This creates a larger interpretive “surface area,” even when the test improves the chance of finding a clinically relevant diagnosis.
Broad-panel testing and expanded clinical yield
Broad-panel testing uses multigene panels, exome sequencing, or genome sequencing to examine many potential causes of disease in one procedure. Its principal advantage is expanded coverage: patients with overlapping symptoms or genetically heterogeneous conditions do not need a separate test for every possible diagnosis. In rare-disease settings, studies of exome and genome sequencing commonly report diagnostic yields of roughly 25% to 50%, depending on patient selection and analytic methods, compared with lower yields from sequential single-gene testing in many heterogeneous disorders.
The same breadth can reveal secondary findings, meaning medically important variants unrelated to the original reason for testing. The ACMG recommends reporting a defined list of pathogenic or likely pathogenic variants in genes associated with preventable or treatable conditions, subject to policy and patient preferences. The proportion of people receiving such findings is often around 1% to 3% in clinical sequencing cohorts, although estimates vary by ancestry, test design, laboratory pipeline, and reporting rules. These results may be beneficial because they enable screening or prevention, but they can also introduce new health decisions into an already stressful clinical encounter.
Targeted testing and bounded uncertainty
Targeted testing evaluates a specific gene, variant, chromosome region, or small disease-focused panel selected to address a defined clinical hypothesis. Its psychological advantage is bounded uncertainty: the patient is more likely to receive information directly connected to the symptoms, family history, or treatment decision that prompted testing. A focused result can be easier to explain, easier to act upon, and less likely to require simultaneous referrals to several specialties.
Targeted testing is not automatically psychologically harmless. A positive result can still produce fear, guilt, stigma, or concern for children and siblings, while a negative result may create false reassurance if the test did not evaluate other relevant genes. In addition, a narrowly selected test may lead to repeated testing when the initial result is uninformative. Thus, targeted testing can reduce immediate information overload while increasing the possibility of later uncertainty, additional appointments, and cumulative testing burden.
Unrelated findings and simultaneous risk disclosure
Unrelated findings are results that do not explain the patient’s presenting condition but may have implications for future disease risk. A simultaneous disclosure occurs when two or more clinically meaningful findings, or a meaningful finding plus one or more uncertain findings, are communicated in the same testing episode. This combination is especially important because psychological burden may arise from the interaction of findings rather than from any single result.
Actionable secondary findings
Actionable secondary findings identify elevated risk for which established surveillance, medication, surgery, or preventive behavior may reduce harm. Examples include pathogenic variants associated with hereditary breast and ovarian cancer, Lynch syndrome, familial hypercholesterolemia, or inherited cardiac arrhythmia. The potential benefit is substantial: a result may prompt earlier colonoscopy, breast imaging, cholesterol treatment, or cardiology assessment.
The psychological cost is that the patient must rapidly shift from the original clinical problem to a new risk-management pathway. When several findings are returned together, people may struggle to distinguish current disease from future susceptibility. A pathogenic variant usually indicates increased risk rather than certainty of disease, but patients may interpret it as a diagnosis. Genetic counseling, confirmatory testing, and staged disclosure can reduce this misunderstanding.
Variants of uncertain significance
A variant of uncertain significance, or VUS, is a genetic change for which available evidence is insufficient to determine whether it contributes to disease. VUS rates vary widely by panel size, disease area, laboratory, and ancestry; broad hereditary-cancer panels may produce VUS results in approximately 20% to 40% of patients in some studies, while rates differ substantially across populations.
Uncertainty can be more burdensome than a clearly negative result because it leaves patients without a stable interpretation. Professional guidance from ACMG and the National Society of Genetic Counselors emphasizes that a VUS should not generally guide irreversible medical decisions. Nevertheless, patients may remember the word “variant” more strongly than the classification “uncertain,” leading to unnecessary imaging, prophylactic procedures, or anxiety about relatives. Larger panels tend to create more opportunities for VUS results because they interrogate more genes and less well-characterized regions.
Multiple findings and cumulative decision load
Cumulative decision load is the mental effort required to understand several risks, evaluate their seriousness, arrange confirmatory testing, and choose among preventive options. For example, a patient could receive one result relevant to cardiac screening, another involving cancer surveillance, and a carrier result affecting reproductive counseling. Each result may be manageable alone, but together they can produce competing appointments, conflicting perceptions of urgency, and worry about transmitting risks to family members.
A useful way to visualize the issue is a comparison chart with testing breadth on the horizontal axis and psychological tasks on the vertical axis. Targeted testing would generally occupy the lower-left portion because it creates fewer interpretive tasks, while broad testing would extend toward higher information yield and higher possible follow-up complexity. The chart should not imply that broad testing always causes greater distress: a definitive diagnosis can reduce years of uncertainty, and an actionable secondary finding can produce reassurance through prevention.
Evidence comparing psychological outcomes
Anxiety, distress, and health-related worry
Studies of genetic testing generally find modest average changes in anxiety and distress, with larger effects concentrated among subgroups receiving unexpected or ambiguous results. Systematic reviews of genetic testing in adults have not consistently shown persistent population-wide psychological harm. Many participants report relief, improved understanding, or greater control after testing, particularly when results clarify a suspected diagnosis or support a concrete prevention plan.
However, average results can conceal clinically important individual experiences. People with a personal or family history of cancer, sudden cardiac death, neurodegenerative disease, or repeated unexplained symptoms may interpret a broad-panel result through an existing lens of threat. Distress may also rise when results are delivered without adequate counseling, when insurance or discrimination concerns are salient, or when the patient lacks access to specialists who can explain the finding.
Uncertainty tolerance and perceived control
Uncertainty tolerance is the capacity to function when the meaning or consequences of a result are not fully known. Targeted tests may appear preferable for people who want a narrow answer, while broad testing may be more acceptable to people who value comprehensive information and are comfortable with probabilistic risk. Importantly, a negative broad panel does not eliminate all inherited risk, and a positive result does not predict an inevitable outcome. Clear explanation of penetrance, residual risk, and test limitations is therefore central to psychological safety.
Research on patient-reported outcomes also suggests that perceived control matters. Patients who understand what they can do next—such as scheduling surveillance, confirming a variant, or sharing a prepared family letter—often report less distress than those who receive risk information without a practical plan. This supports a counseling model that treats action planning as part of the test rather than as an optional service after the result.
Clinical strategies for reducing burden
Choice, consent, and staged disclosure
Informed consent for broad-panel testing should explain the possibility of primary findings, secondary findings, carrier status, pharmacogenomic results, VUS results, and findings that may affect relatives. Patients should be told what categories they may opt out of, when that option exists, and how results will be reinterpreted over time. Staged disclosure can prioritize the result most relevant to the immediate clinical question before addressing unrelated findings in a separate counseling session.
Result communication and follow-up
Results should be communicated using absolute and comparative risk where possible, rather than relying only on labels such as “high risk.” Confirmatory testing is important before irreversible action, particularly when a result is unexpected. A written summary, referral pathway, family communication support, and access to a genetic counselor can reduce the cognitive burden of remembering several recommendations.
- Use targeted testing when the clinical question is well defined and additional information would not change management.
- Use broad testing when genetic heterogeneity, severe unexplained disease, or the need to avoid serial testing justifies expanded coverage.
- Separate actionable findings from VUS results and explain that they should not be managed in the same way.
- Offer referral, confirmatory testing, and a written follow-up plan when unrelated risks are identified.
Conclusion: balancing information gain against psychological burden
Psychological burden of broad-panel genomic testing is best understood as a balance between expanded clinical yield and expanded interpretive responsibility. Targeted testing narrows the question and may reduce immediate information overload, but it can miss relevant diagnoses and lead to repeated testing. Broad panels can shorten the diagnostic journey and reveal actionable secondary findings, yet they also increase the chance of VUS results, unrelated disease risks, and simultaneous decisions that challenge uncertainty tolerance.
The evidence does not support treating broad testing as inherently psychologically harmful or targeted testing as inherently safe. The strongest predictors of burden are unexpected results, ambiguity, poor communication, limited access to follow-up, and the number of decisions presented at once. Health systems should therefore measure both diagnostic yield and patient-reported outcomes, including anxiety, understanding, decisional conflict, and confidence in follow-up. Patients considering testing should ask what will be analyzed, which secondary findings will be returned, whether they can decline categories of results, and who will help interpret them. Further reading from ACMG, the National Human Genome Research Institute, the National Society of Genetic Counselors, and peer-reviewed systematic reviews can support shared decision-making.
Sources: American College of Medical Genetics and Genomics, “ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing,” https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Secondary_Findings_Implementation_Guide.aspx; National Human Genome Research Institute, “Genetic Counseling,” https://www.genome.gov/Health/Genetic-Disorders/Genetic-Counseling; National Society of Genetic Counselors, “Position Statement: Genetic Testing of Children,” https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements; American College of Medical Genetics and Genomics and Association for Molecular Pathology, “Standards and Guidelines for the Interpretation of Sequence Variants,” https://pubmed.ncbi.nlm.nih.gov/25741868/; Manolio TA et al., “Finding the missing heritability of complex diseases,” Nature, https://www.nature.com/articles/nature08494; Sanderson SC et al., “Psychological and behavioral impact of genetic testing,” Genetics in Medicine, https://pubmed.ncbi.nlm.nih.gov/21941115/; Middleton A et al., “Attitudes of nearly 7000 health professionals, patients and members of the public to genomic secondary findings,” European Journal of Human Genetics, https://pubmed.ncbi.nlm.nih.gov/28332584/; Miller DT et al., “ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing,” Genetics in Medicine, https://pubmed.ncbi.nlm.nih.gov/37376175/.
